Status:
COMPLETED
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Lead Sponsor:
Guangdong Association of Clinical Trials
Collaborating Sponsors:
The First Hospital of Jilin University
Ruijin Hospital
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Platinum-based combination chemotherapy, such as gemcitabine-carboplatin, is one of the standard first-line therapy for advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor t...
Detailed Description
Nowadays,EGFR mutation status is unknown for most of the advanced NSCLC patients in clinical practice.Those patients with high probability of EGFR mutation maybe could get benefit from gefitinib as fi...
Eligibility Criteria
Inclusion
- After two cycles chemotherapy(gemcitabine plus carboplatin), patients with stable disease(SD) by RECIST1.1.
- Patients between 18 and 75 years of age.
- Present with histologically proven or cytological diagnosis of adenocarcinoma NSCLC Stage IIIB or IV as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer, that is not amenable to curative therapy,such as surgery or radiotherapy and so on.
- No prior systemic chemotherapy or targeted therapy for lung cancer before screening.
- Never smokers(defined as having smoked less than 100 cigarettes in their lifetime ) or light ex-smokers (defined as having ceased smoking at least 15 years before Day 1 of study treatment and having smoked 10 pack-years or fewer).
- EGFR mutation status unknown.
- ECOG performance status of 0 or 1.
- Adequate organ function.
- Prior radiation therapy allowed to \<25% of the bone marrow . Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment.
- Signed informed consent document on file.
- Estimated life expectancy of ≥12 weeks.
- Patient compliance and geographic proximity that allow adequate follow up.
Exclusion
- Known severe hypersensitivity to gefitinib.
- Sympotomatic patients with brain metastases.
- Pleural effusion or pericardiac effusion that cannot be controlled by drainage or other procedures.
- Inability to comply with protocol or study procedures.
- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
- Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- Interstitial pneumonia.
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT01404260
Start Date
June 1 2011
End Date
October 1 2015
Last Update
January 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030